THE Pfizer Inc invests the huge profits from vaccines and them treatments her for her Covid-19 in the development of preparations for fight cancerthe CEO of the pharmaceutical giant emphasized today Albert Burlanotably highlighting the acquisition of Seagen Inc for $43 billion.

“Pfizer is investing all of our Covid revenue in 2021 and 2022, as well as what we will earn in 2023, to acquire technology and products that we believe will enable us to fight cancer,” Burla said in a webinar that organized by Reuters.

In collaboration with the German BioNTech, Pfizer developed in 2020 one of the most widespread vaccines against Covid-19. It was followed by the antiviral drug Paxlovid to treat the disease caused by the coronavirus.

In 2021, Pfizer’s revenue will reach approximately $80 billion and in 2022, it will exceed $100 billion.

Like other vaccine makers, it plans to make the next batches of Covid-19 vaccines available commercially rather than directly to the US government. As a result, the cost of Covid-19 vaccination in the US is expected to quadruple to around $110-130 per vaccine dose.

The expected drop in revenue from vaccines and treatments for Covid-19, and the increasing competition Pfizer’s drugs face from cheaper generics, is forcing the company that starred in the fight against the pandemic to readjust its strategic goals.

In this context, Pfizer acquired other companies, of which Seagen stands out, which develops targeted therapies for various types of cancer. It also acquired Biohaven Pharmaceutical Holding (specializing in migraine drugs) for $11.6 billion, Arena Pharmaceuticals (developing a treatment for ulcerative colitis) for $6.7 billion, and Global Blood Therapeutics (with specializing in the treatment of sickle cell disease) for $5.4 billion.